

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

06267.0085

U.S. APPLICATION NO.  
(If known, see 37CFR1.5)

known, see 37 CFR 1.51

**107070689**

INTERNATIONAL APPLICATION NO.

PCT/FI00/00761

INTERNATIONAL FILING DATE

September 8, 2000

PRIORITY DATE CLAIMED

September 10, 1999

TITLE OF INVENTION

## PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN

APPLICANT(S) FOR DO/EO/US


**Reijo BÄCKSTRÖM; Päivi GRANVIK; Ritva HAIKALA; Sirpa PELTTARI; Eva SAUKKO; Reija YRJÖLÄ**

Applicant(s) herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau.
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed with the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154 (d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

**Items 11 to 20 below concern document(s) or information included:**

- |     |                                        |                                                                                                                   |
|-----|----------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| 11. | <input checked="" type="checkbox"/>    | Information Disclosure Statement under 37 CFR 1.97 and 1.98                                                       |
| 12. | <input type="checkbox"/>               | An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. |
| 13. | <input checked="" type="checkbox"/>    | A FIRST preliminary amendment.                                                                                    |
| 14. | <input type="checkbox"/>               | A SECOND or SUBSEQUENT preliminary amendment.                                                                     |
| 15. | <input type="checkbox"/>               | A Substitute specification.                                                                                       |
| 16. | <input type="checkbox"/>               | A change of power of attorney and/or address letter.                                                              |
| 17. | <input type="checkbox"/>               | A computer-readable form of the sequence listing in accordance with PCT Rule 13ter 2 and 35 U.S.C. 1.821-1.825.   |
| 18. | <input type="checkbox"/>               | A second copy of the published international application under 35 U.S.C. 154 (d)(4).                              |
| 19. | <input type="checkbox"/>               | A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).          |
| 20. | <input checked="" type="checkbox"/>    | Other items or information:                                                                                       |
|     | a. <input checked="" type="checkbox"/> | Copy of cover page of International Publication No. WO01/19334A2                                                  |
|     | b. <input type="checkbox"/>            | Copy of Notification of Missing Requirements.                                                                     |
|     | c. <input type="checkbox"/>            |                                                                                                                   |

U.S. APPLICATION NO. (If known, see 37CFR 1.5) <b>10/070689</b>		INTERNATIONAL APPLICATION NO. PCT/FI00/00761		ATTORNEY'S DOCKET NUMBER 06267.0085	
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b>  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1040.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$890.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$740.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$710.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33 (1)-(4) ..... <b>\$100.00</b>  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	21	- 20 =	1	x \$18.00	\$18.00
Independent Claims	3	- 3 =	0	x \$84.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+\$280.00	\$
<b>TOTAL OF THE ABOVE CALCULATIONS =</b>					\$908.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
<b>SUBTOTAL =</b>					\$908.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>					908.00
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				\$	
<b>TOTAL FEES ENCLOSED =</b>					\$908.00
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>908.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-0916</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card</b> <b>information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
<b>SEND ALL CORRESPONDENCE TO:</b> Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 1300 I Street, N.W. Washington, D.C. 20005-3315					
DATED: March 8, 2002				 SIGNATURE Ernest F. Chapman, Reg. No. 25,961 NAME/REGISTRATION NO.	

PATENT  
Attorney Docket No.: 06267.0085

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
 )  
**Reijo BÄCKSTRÖM et al.** )  
 )  
Application No.: Unassigned ) Group Art Unit: Unassigned  
 )  
Filed: Filed Herewith ) Examiner: Unassigned

For: PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN being a National Stage filing of PCT International Application No. PCT/FI00/00761, filed on September 8, 2000

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**Preliminary Amendment**

Please amend the application as follows:

**In the abstract:**

Please add the abstract attached to the end of this Preliminary Amendment.

**In the specification:**

Please amend the specification as follows:

Page 1, after the title, insert a first paragraph as follows:

-- This application is a national stage filing of PCT International Application No. PCT/FI00/00761, filed on September 8, 2000. This application also claims the benefit of priority to Finnish patent application no. 19991925, filed on September 10, 1999. --

**In the claims:**

Please amend claims 1-10 and 13 and add new claims 14-21 as follows:

1. (Amended) A pharmaceutical aqueous solution comprising levosimendan or a salt thereof as an active ingredient, the pH-value of the solution being lower than 5, and optionally a solubility enhancing agent.

**Attorney Docket No. 06267.0085**

2. (Amended) A solution according to claim 1, the pH-value of the solution being in the range of from about 3 to about 4.2.

3. (Amended) An aqueous intravenous infusion solution comprising levosimendan or a salt thereof as an active ingredient, the pH-value of the solution being lower than 5, and optionally a solubility enhancing agent.

4. (Amended) A solution according to claim 3, the pH-value of the solution being in the range of from about 3 to about 4.2.

5. (Amended) A solution according to claim 3, wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.

6. (Amended) A pharmaceutical solution, comprising  
 (a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient,  
 (b) a pharmaceutically acceptable organic solvent comprising ethanol,  
 (c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4, and optionally  
 (d) a water-solubility enhancing agent.

7. (Amended) A solution according to claim 6, wherein the amount of said solvent is 90-99.9% by weight of the solution.

8. (Amended) A solution according to claim 6, wherein the amount of said organic acid is 0.005-2% by weight of the solution.

9. (Amended) A solution according to claim 6, wherein the pharmaceutically acceptable organic acid is a 2-hydroxy alkanoic acid.

10. (Amended) A solution according to claim 9, wherein the pharmaceutically acceptable organic acid is citric acid, lactic acid, tartaric acid or malic acid.

**Attorney Docket No. 06267.0085**

13. (Amended) A solution according to claim 6, comprising  
(a) levosimendan or a pharmaceutically acceptable salt thereof in an amount of 0.01-1.0% by weight,

(b) dehydrated ethanol in an amount of 95-99.5% by weight,

(c) citric acid in an amount of 0.03-0.6% by weight, and

(d) polyvinylpyrrolidone in an amount of 0.5-2% by weight.

14. (New) A solution according to claim 1, wherein the pH-value of the solution is about 4.5 or lower.

15. (New) A solution according to claim 3, wherein the pH-value of the solution is about 4.5 or lower.

16. (New) A solution according to claim 4, wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.

17. (New) A solution according to claim 6, wherein the solution is an intravenous infusion concentrate.

18. (New) A solution according to claim 6, wherein the amount of said solvent is 95-99.9% by weight of the solution.

19. (New) A solution according to claim 6, wherein the amount of said organic acid is 0.01-1% by weight of the solution.

20. (New) A solution according to claim 7, wherein the amount of said organic acid is 0.005-2% by weight of the solution.

21. (New) A solution according to claim 7, wherein the amount of said organic acid is 0.01-1% by weight of the solution.

**Attorney Docket No. 06267.0085**

**Remarks**

Claims 1-21 are pending in this application. Claims 1-10 and 13 have been amended for formalistic reasons to place the claims in condition for examination in the U.S. Patent and Trademark Office after entering the U.S. national stage. None of the amendments narrow the scope of the original claims.


Support for new claims 14-21 appears in the original claims.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:

  
\_\_\_\_\_  
Steven J. Scott  
Reg. No. 43,911

Date: March 5, 2002

**Attorney Docket No. 06267.0085**

**Appendix Detailing Amendments to Claims**

1. (Amended) A pharmaceutical aqueous solution comprising levosimendan or a salt thereof as an active ingredient, the pH-value of the solution being lower than 5, [preferably about 4.5 or lower,] and optionally a solubility enhancing agent.

2. (Amended) A solution according to claim 1, the pH-value of the solution being in the range of from about 3 to about 4.2.

3. (Amended) An aqueous [Aqueous] intravenous infusion solution comprising levosimendan or a salt thereof as an active ingredient, the pH-value of the solution being lower than 5, [preferably about 4.5 or lower,] and optionally a solubility enhancing agent.

4. (Amended) A solution according to claim 3, the pH-value of the solution being in the range of from about 3 to about 4.2.

5. (Amended) A solution according to claim 3 [or 4], wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.

6. (Amended) A pharmaceutical solution, [particularly an intravenous infusion concentrate,] comprising

(a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient,

(b) a pharmaceutically acceptable organic solvent comprising ethanol,

(c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4, and optionally

(d) a water-solubility enhancing agent.

7. (Amended) A solution according to claim 6, wherein the amount of said solvent is 90-99.9% [, preferably 95-99.9%,] by weight of the solution.

8. (Amended) A solution according to claim 6 [or 7], wherein the amount of said organic acid is 0.005-2% [, preferably 0.01-1%,] by weight of the solution.

**Attorney Docket No. 06267.0085**

9. (Amended) A solution according to claim 6 [any of claims 6-8], wherein the pharmaceutically acceptable organic acid is a 2-hydroxy alkanolic acid.

10. (Amended) A solution according to claim 9, wherein the pharmaceutically acceptable organic acid is citric acid, lactic acid, tartaric acid or malic acid.

13. (Amended) A solution according to claim 6, comprising  
 (a) levosimendan or a pharmaceutically acceptable salt thereof in an amount of 0.01-1.0% by weight,  
 (b) dehydrated ethanol in an amount of 95-99.5% by weight,  
 (c) citric acid in an amount of 0.03-0.6% by weight, and  
 (d) polyvinylpyrrolidone in an amount of 0.5-2% by weight.



**Attorney Docket No. 06267.0085**

**Abstract**

Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment of congestive heart failure.


## PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN

### Technical field

The present invention relates to levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan, or (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, is useful in the treatment of congestive heart failure.

### Background of the invention

Levosimendan, which is the (-)-enantiomer of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile, and methods for its preparation are described in EP 565546 B1 and WO 97/35841. Levosimendan is potent in the treatment of heart failure and has significant calcium dependent binding to troponin. Levosimendan is represented by the formula:



The hemodynamic effects of levosimendan in man are described in Sundberg, S. et al., Am. J. Cardiol., 1995; 75: 1061-1066. Pharmacokinetics of levosimendan in man after i.v. and oral dosing is described in Sandell, E.-P. et al., J. Cardiovasc. Pharmacol., 26(Suppl.1), S57-S62, 1995. The use of levosimendan in the treatment of myocardial ischemia is described in WO 93/21921. Transdermal compositions of levosimendan are described in WO 98/01111. Clinical studies have confirmed the beneficial effects of levosimendan in heart failure patients.

Administration of a drug by parenteral, e.g. intravenous, administration provides a number of advantages including the following:

- an almost immediate response may be obtained by administering by intravenous injection or infusion a solution, usually aqueous, of the drug;  
- the therapeutic response may be more readily controlled by administering the drug parenterally; and  
5 - a drug can be administered parenterally to a patient when it cannot be administered orally because of the unconscious state of the patient, or because of inactivation or lack of absorption in the intestinal tract.

10 The manufacture of levosimendan solutions, and particularly solutions suitable for intravenous use, involves a number of problems which are caused by the sensitivity of levosimendan against chemical and physical influences. In solutions levosimendan is sensitive to chemical degradation which limits the shelf-life of solutions and may produce undesirable degradation products. Levosimendan is also poorly soluble in water and precipitates easily from aqueous solutions. The precipitation of intravenous  
15 solutions is extremely dangerous because particulate material may occlude the blood vessels. The solubility of levosimendan decreases further strongly when the pH is lowered from neutral, so that low pH would in principle seem unfavourable. Thus, there is a need for improved aqueous formulations of levosimendan which are chemically and physically stable under prolonged storage and suitable for intravenous administration.

20

### Summary of the invention

It has now been found that the chemical stability of levosimendan solutions can be significantly improved if the pH of the solution is lowered from neutral to lower than  
25 5, preferably to 4.5 or lower, most preferably to 3 – 4.2. Furthermore, it has been found that the precipitation of the active ingredient can be prevented in such chemically stable solutions.

Thus, in one aspect, the present invention provides a pharmaceutical aqueous  
30 solution with improved stability comprising

- (a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient, the pH-value of the solution being lower than 5, preferably about 4.5 or lower, most preferably from about 3 to about 4.2, and optionally
- (b) a solubility enhancing agent.

35

In another aspect, the invention provides an aqueous intravenous infusion solution with improved stability comprising

(a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient, the pH-value of the solution being lower than 5, preferably about 4.5 or lower, most preferably from about 3 to about 4.2; and optionally

(b) a solubility enhancing agent.

5

Still in another aspect the invention provides an intravenous infusion concentrate, particularly to be diluted with an aqueous vehicle before use, comprising

(a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient;

10

(b) organic solvent comprising ethanol;

(c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4; and optionally

(d) a solubility enhancing agent.

15

#### Detailed description of the invention

Levosimendan is crystalline powder at room temperature and has pKa of 6.26. At room temperature the solubility of levosimendan in phosphate buffer is 0.4 mg/ml (pH 7.4), 0.03 mg/ml (pH 6) and 0.02 mg/ml (pH 2). Thus, the water solubility of  
20 levosimendan decreases quite sharply when pH is lowered below neutral. However, it has been found that it is possible to prepare pharmaceutically acceptable aqueous solutions of levosimendan with pH lower than 5. Such solutions are chemically and physically stable over an extended period of time and, therefore, they are particularly suitable for pharmaceutical use.

25

In one aspect, the invention provides a pharmaceutical composition which comprises levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient in an aqueous solution with pH lower than 5, preferably about 4.5 or lower, and most preferably from about 3 to about 4.2. The composition of the invention is  
30 particularly useful in various pharmaceutical applications in which levosimendan must be stored in the form of an aqueous solution for an extended period of time.

35

The therapeutically effective amount of levosimendan included in the composition of the invention depends e.g. on the administration route of the composition, the treatment procedure and the condition to be treated. In general, the amount of levosimendan in the composition is within the range of about 0.001 - 5 mg/ml. The daily dosage of levosimendan in man is within the range of about 0.1 - 50 mg, preferably about 0.2 - 20 mg, depending on the administration route, age, body

weight and condition of the patient. Preferred peak plasma levels of levosimendan in steady state for the treatment of congestive heart failure are within the range of from about 1 to about 300 ng/ml, more preferably from about 10 to about 150 ng/ml, and especially from about 20 to about 60 ng/ml. Levosimendan can be administered  
5 intravenously with the infusion rate in the range of about 0.005 - 100 µg/kg/min, typically 0.01 to 10 µg/kg/min, more typically about 0.02 to 1 µg/kg/min. For the treatment of heart failure with continuous infusion the suitable rate is 0.05 - 0.4 µg/kg/min of levosimendan.

10 Salts of levosimendan may be prepared by known methods. Pharmaceutically acceptable salts are useful as active medicaments, however, preferred salts are the salts with alkali or alkaline earth metals.

The control of pH of the composition is essential to maintain the required  
15 stability of the active ingredient. Therefore, a suitable pharmaceutically acceptable acidic compound or buffer system in an amount effective to maintain the pH of the composition in the desired range, may be used. Preferred acidic compounds include pharmaceutically acceptable organic acids having pKa in the range of from about 2 to about 4. Such acids include 2-hydroxy alcanoic acids, such as citric acid, lactic acid,  
20 tartaric acid or malic acid. If a pharmaceutically acceptable buffer system is used, it is selected from a group of buffers that are effective to maintain pH below 5, preferably at 4.5 or lower, most preferably in the range of about 3 - 4.2, which buffers are well known in the art. Most preferably the buffer may be selected from citrate, acetate, phosphate and lactate buffers. The preparation of buffer systems is well known for one  
25 skilled in the art. In general, the acidic compound or buffer is used in an amount necessary to adjust the pH into the desired range. However, the amount used must be pharmaceutically acceptable.

The composition of the invention may also comprise a solubility enhancing  
30 agent. The term "solubility enhancing agent" means herein a substance capable of increasing the amount of levosimendan that can be maintained in a dissolved state in an aqueous solution, including the prevention of crystallization or crystalline growth of levosimendan. Suitable solubility enhancing agents include co-solvents such as ethanol or propylene glycol, surfactants and polymeric substances such as polysorbates,  
35 polyalkylene glycols (e.g. polyethylene glycol), poloxamers or polyvinylpyrrolidone, and oily fatty acids and their mono- or diglycerol esters such as linoleic acid or glycerol monolaurate. In general, the amount of the solubility enhancing agent is within the range of about 0.001 - 80 %, preferably 0.005 - 10 %, most preferably 0.01 - 5 %, by

weight of the composition. For intravenous administration, wherein the choice of acceptable adjuvants is limited, polyvinylpyrrolidone or ethanol or a mixture thereof is the preferred solubility enhancing agent polyvinylpyrrolidone being the most preferred. Suitable polyvinyl pyrrolidones are those with a number average weight below 40,000, more suitably below 5000, and particularly about 2,500. Such a polyvinyl pyrrolidone is exemplified by Kollidon PF12 (registered trademark).

It will be understood that various additives commonly used in this field of the art, such as preservatives, can be also included in the composition of the invention.

In another aspect, the invention provides an aqueous intravenous solution comprising levosimendan or a salt thereof as an active ingredient the pH-value of the solution being lower than 5, preferably about 4.5 or lower, and most preferably from about 3 to about 4.2. The aqueous intravenous solution, which can be in a form of e.g. an injection or infusion solution, of the invention is chemically and physically stable under storage conditions over an extended period of time. Preferably the aqueous intravenous solution is a ready to use intravenous solution for infusion or bolus injection.

The amount of levosimendan included in the aqueous intravenous solution of the invention depends e.g. on the treatment procedure and the condition to be treated, but is generally a therapeutically effective amount. The amount may vary e.g. within the range of about 0.001 - 1.0 mg/ml, preferably about 0.005 - 0.5 mg/ml, most preferably about 0.01 - 0.1 mg/ml.

For maintaining the pH of the aqueous intravenous composition of the invention in the desired range a suitable pharmaceutically acceptable acidic compound or buffer system may be used as described above.

The aqueous intravenous composition of the invention may also comprise a solubility enhancing agent for increasing the amount of levosimendan that can be maintained in a dissolved state in an aqueous solution, including the prevention of crystallization or crystalline growth of levosimendan. For intravenous administration, wherein the choice of acceptable adjuvants is limited, polyvinylpyrrolidone or ethanol or a mixture thereof is the preferred solubility enhancing agent polyvinylpyrrolidone being the most preferred. The amount of the solubility enhancing agent in the aqueous intravenous composition is generally within the range of about 0.001 - 20 %, preferably 0.005 - 5 %, by weight of the aqueous intravenous composition. The preferred amount

of polyvinylpyrrolidone is within the range of about 0.005 – 0.5 % by weight of the aqueous intravenous composition.

5 The aqueous intravenous composition of the invention may also comprise a physiologically and pharmaceutically acceptable compound effective to render the aqueous intravenous composition isotonic, i.e. to have an osmotic pressure corresponding to that of a 0.9 % solution of sodium chloride. Typical examples of such compounds are chloride salts such as NaCl and saccharides such as sorbitol, mannitol and dextrose/glucose. The preparation of isotonic solutions is well known for one  
10 skilled in the art.

The aqueous intravenous composition of the invention may be prepared e.g. by dissolving levosimendan and other adjuvants into sterile isotonic aqueous vehicles, e.g. 0.9 % solution of sodium chloride while stirring. Alternatively a suitable amount of  
15 isotonic rendering compound is dissolved together with levosimendan and other adjuvants into aqueous vehicle, e.g. sterile distilled water. The solution may be also prepared by dissolving levosimendan and other adjuvants first in suitable solvent such as ethanol, and diluting the solution with sterile isotonic aqueous vehicles. The bulk solution is filtered and filled into infusion bottles or ampules. The product is sterilized  
20 preferably using autoclaving in a manner known in the art.

In yet another aspect the invention provides a pharmaceutical solution, particularly an intravenous infusion concentrate to be diluted with an aqueous vehicle before use, comprising (a) levosimendan or a pharmaceutically acceptable salt thereof  
25 as an active ingredient, (b) pharmaceutically acceptable organic solvent comprising ethanol, preferably dehydrated ethanol, and (c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from about 2 to about 4. It has been found that the pharmaceutically acceptable organic acid having pKa in the range of from about 2 to about 4 improves the stability of levosimendan in the  
30 concentrate solutions of the invention. It has also been found that the concentrate solutions of the invention can be successfully diluted with an aqueous infusion vehicle to obtain aqueous intravenous solutions which are chemically and physically stable over an extended period of time.

35 The amount of pharmaceutically acceptable organic solvent is generally within the range of 90 – 99.9 %, preferably 95 – 99.9 %, by weight of the concentrate solution of the invention. Typically at least about 50 % by weight of the solvent is ethanol. More suitably, the solvent consists essentially of ethanol, whereby at least 90 %, preferably at

least 95 %, more preferably at least 99 %, by weight of the solvent is ethanol. Most preferably the solvent consists solely of ethanol, preferably dehydrated ethanol.

The amount of said pharmaceutically acceptable organic acid is preferably  
5 within the range of 0.005 – 2 %, preferably 0.01 – 1 %, by weight of the concentrate solution. Said pharmaceutically acceptable organic acid is a preferably a 2-hydroxy alkanoic acid. Such acids include citric acid, lactic acid, tartaric acid and malic acid the most preferred being citric acid.

10 The amount of levosimendan included in the concentrate solution of the invention is generally an amount which is therapeutically effective. The amount may vary e.g. within the range of about 0.1 - 10 mg/ml, preferably about 0.5 – 8 mg/ml, most preferably about 1 – 5 mg/ml.

15 The concentrate solution of the invention may also comprise a solubility enhancing agent for increasing the amount of levosimendan that can be maintained in a dissolved state in an aqueous solution, including the prevention of crystallization or crystalline growth of levosimendan. The amount of the solubility enhancing agent in the concentrate solution of the invention is generally within the range of about 0.01 - 5 %,  
20 by weight of the composition. The solubility enhancing agent can be selected as described above. The most preferred solubility enhancing agent is polyvinylpyrrolidone. The preferred amount of polyvinylpyrrolidone is generally within the range of about 0.5 - 2 %, by weight of the concentrate composition.

25 A particularly preferred concentrate solution for intravenous infusion comprises  
(a) levosimendan or a pharmaceutically acceptable salt thereof in amount of 0.01 – 1.0 % by weight,  
(b) dehydrated ethanol in amount of 95 – 99.5 % by weight,  
(c) citric acid in amount of 0.03 – 0.6 % by weight, and  
30 (d) polyvinylpyrrolidone in amount of 0.5 – 2 % by weight.

The concentrate solution may be prepared by dissolving stability enhancing organic acid, levosimendan and the optional solubility enhancing agent and possible  
35 other additives to the solvent in the sterilized preparation vessel under stirring. The resulting bulk solution is filtered through a sterile filter. The sterilization method of the product is preferably a sterile filtration, because ethanol solution cannot be autoclaved due to the explosion risk. The sterile filtered bulk solution is aseptically filled into injection vials and closed with rubber closures.



The concentrate solution for intravenous infusion is diluted with an aqueous vehicle before use. Typically the concentrate solution is diluted with aqueous isotonic vehicles for intravenous infusion, such as 5 % glucose solution or 0.9 % NaCl solution.

The concentrate infusion is diluted such that an aqueous intravenous solution is obtained, wherein the amount of levosimendan is generally within the range of about 0.001 - 1.0 mg/ml, preferably about 0.005 - 0.5 mg/ml, most preferably about 0.01 - 0.1 mg/ml, depending e.g. on the treatment procedure and the condition to be treated.

The invention is illustrated but in no way limited, by the following examples.

#### Example 1. Concentrate solution for intravenous infusion

(a) levosimendan	2.5 mg/ml
(b) Kollidon PF12	10 mg/ml
(c) citric acid	2 mg/ml
(d) dehydrated ethanol	ad 1 ml (785 mg)

The concentrate solution was prepared by dissolving citric acid, Kollidon PF121 and levosimendan to dehydrated ethanol in the sterilized preparation vessel under stirring. The resulting bulk solution was filtered through a sterile filter (0.22  $\mu$ m). The sterilization method of the product was sterile filtration, because ethanol solution cannot be autoclaved due to the explosion risk. The sterile filtered bulk solution was then aseptically filled into 8 ml and 10 ml injection vials (with 5 ml and 10 ml filling volumes) and closed with rubber closures. The product has a shelf-life of 2 years in 2 - 8 °C.

#### Example 2.

The effect of citric acid on the chemical stability of levosimendan in ethanolic infusion concentrate solutions stored in different temperatures was studied. The solutions were prepared as described in Example 1. The results are shown in Tables 1 and 2. In the Tables "OR-1746" refers to (4-Ethoxy-6-imino-5-[[4-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]hydrazono}-5,6-dihydro-1(H)-pyrimidin-2-ylidene)-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenylazo]acetonitrile.

Table 1. Effect of citric acid on the chemical stability of levosimendan. All solutions contain levosimendan (1.25 mg/ml), Kollidon PF12 (10 mg/ml) and dehydrated ethanol (ad 1 ml).

Citric acid mg/ml	Storage time / Amount of degradation product (OR-1746)	
	2 – 8 °C	40 °C
0	5 weeks / 0.34 %	5 weeks / 10.9 %
0.25	13 weeks / 0.29 %	13 weeks / 6.2 %
0.50	13 weeks / 0.20 %	13 weeks / 4.4 %
0.75	13 weeks / 0.16 %	13 weeks / 3.5 %
1.00	13 weeks / 0.13 %	13 weeks / 3.0 %
1.50	13 weeks / 0.10 %	13 weeks / 2.2 %
2.00	13 weeks / 0.10 %	13 weeks / 1.7 %

5

Table 2. Effect of citric acid on the chemical stability of levosimendan. All solutions contain levosimendan (2.50 mg/ml), Kollidon PF12 (10 mg/ml) and dehydrated ethanol (ad 1 ml).

10

Citric acid mg/ml	Storage time / Amount of degradation product (OR-1746)	
	2 – 8 °C	40 °C
0	12 months / 3.94 %	nd
2.0	4 months / 0.20 %	4 months / 5.6 %
	12 months / 0.39 %	nd
	18 months / 0.59 %	nd
2.5	4 months / 0.16 %	4 months / 3.2 %
	12 months / 0.28 %	nd
	18 months / 0.47 %	nd

nd = not determined

The results show that citric acid significantly improves the chemical stability of levosimendan in infusion concentrate solutions.

15

Example 3. Aqueous solution for infusion, pH 3.9

(a) levosimendan	0.025 mg/ml
(b) Kollidon PF12	0.10 mg/ml
(c) citric acid	0.02 mg/ml
(d) ethanol	7.85 mg/ml
(e) sodium chloride	9.0 mg/ml
(e) water	ad 1 ml

The above aqueous infusion solution was obtained by diluting the infusion concentrate solution of Example 1 with isotonic (0.9 %) sodium chloride solution such that the resulting aqueous solution contained 0.025 mg/ml of levosimendan. The diluted solution was clear with no precipitation.

The chemical stability of levosimendan in the aqueous solution of Example 3 was studied after 24 hour storage (at room temperature) and after one month storage (at 2 – 8 °C). The results are shown in Table 3. "OR-1420" refers to (E)-2-cyano-2-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]acetamide.

Table 3. The chemical stability of levosimendan in a solution of Example 3 after the storage of 24 hours (at room temperature 25 °C) and after the storage of one month (at 2 – 8 °C).

	0 h	24 h	1 month
Degradation product OR-1420	<	<	0.1 %
Degradation product OR-1746	0.1 %	0.1 %	<
Unknown degradation products	<	<	<
pH	3.9	nd	3.9

< = under quantitation limit 0.1 %

nd = not determined

For comparison, the chemical stability of levosimendan in Reference solutions having pH of 7 – 8 was studied after the storage of 2 and 5 days at 8 - 15 °C and room temperature. The results are shown in Table 4.

Reference solutions:

(a) levosimendan	0.01 - 0.25 mg/ml
(b) sodium chloride	9 mg/ml
(c) sodium carbonate monohydr.	0.02 – 0.5 mg/ml

(d) hydrochloric acid 0.1 M to adjust pH to 7 - 8  
(e) water ad 1 ml

5 Table 4. The chemical stability of levosimendan in Reference solutions (0.01, 0.1 and 0.25 mg/ml of levosimendan) having pH of 7 - 8 after the storage of 2 and 5 days at 8 - 15 °C and room temperature (25 °C).

	Levosimendan mg/ml	0 h	2 days 8-15°C / 25°C	5 days 8-15°C / 25°C
Degradation product OR-1420	0.01	<	1.6 % / 3.3 %	2.2 % / 6.0 %
	0.1	1.5 %	1.1 % / 1.8 %	1.8 % / 5.3 %
	0.25	0.4 %	0.8 % / 2.2 %	1.4 % / 4.2 %
Unknown degradation products	0.01	nd	nd	nd
	0.1	<	0.2 % / 0.4 %	0.2 % / 0.6 %
	0.25	<	0.3 % / 0.5 %	0.3 % / 0.9 %
pH	0.01	7.2	7.2 / 7.3	7.3 / 7.3
	0.1	7.8	7.8 / 7.8	8.0 / 8.0
	0.25	7.8	7.8 / 7.8	8.0 / 8.0

< = under quantitation limit 0.1 %

nd = not determined

10

The results show that degradation of levosimendan is significantly retarded in the solution of Example 3 compared to Reference solutions. In the Reference solutions significant amounts of degradation products are formed already after the storage of 5 days, whereas the solution of Example 3 is stable even after the storage of one month. It  
15 can be also noted that the pH tends to increase in Reference solutions.

## CLAIMS

1. A pharmaceutical aqueous solution comprising levosimendan or a salt thereof as an active ingredient the pH-value of the solution being lower than 5, preferably about 4.5 or lower, and optionally a solubility enhancing agent.
2. A solution according to claim 1 the pH-value of the solution being in the range of from about 3 to about 4.2.
3. Aqueous intravenous infusion solution comprising levosimendan or a salt thereof as an active ingredient the pH-value of the solution being lower than 5, preferably about 4.5 or lower, and optionally a solubility enhancing agent.
4. A solution according to claim 3 the pH-value of the solution being in the range of from about 3 to about 4.2.
5. A solution according to claim 3 or 4, wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.
6. A pharmaceutical solution, particularly an intravenous infusion concentrate, comprising
- (a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient,
  - (b) pharmaceutically acceptable organic solvent comprising ethanol,
  - (c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4, and optionally
  - (d) a water-solubility enhancing agent.
7. A solution according to claim 6, wherein the amount of said solvent is 90 – 99.9 %, preferably 95 – 99.9 %, by weight of the solution.
8. A solution according to claim 6 or 7, wherein the amount of said organic acid is 0.005 – 2 %, preferably 0.01 – 1 %, by weight of the solution.
9. A solution according to any of claims 6 - 8, wherein pharmaceutically acceptable organic acid is a 2-hydroxy alkanoic acid.
10. A solution according to claim 9, wherein pharmaceutically acceptable organic acid is citric acid, lactic acid, tartaric acid or malic acid.
11. A solution according to claim 6, wherein the amount of the water-solubility enhancing agent is 0.1 – 5 % by weight.
12. A solution according to claim 6, wherein the water-solubility enhancing agent is polyvinylpyrrolidone.
13. A solution according to claim 6 comprising
- (a) levosimendan or a pharmaceutically acceptable salt thereof in amount of 0.01 – 1.0 % by weight,
  - (b) dehydrated ethanol in amount of 95 – 99.5 % by weight,

- (c) citric acid in amount of 0.03 – 0.6 % by weight, and
- (d) polyvinylpyrrolidone in amount of 0.5 – 2 % by weight.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
**WO 01/19334 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 9/00**

(FI). YRJÖLÄ, Reija [FI/FI]; Fransilantie 4, FIN-36110 Ruutana (FI).

(21) International Application Number: **PCT/FI00/00761**

(74) Agent: **ORION CORPORATION**; Orion Pharma, Industrial Property Rights, P.O. Box 65, FIN-02101 Espoo (FI).

(22) International Filing Date:  
8 September 2000 (08.09.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
19991925 10 September 1999 (10.09.1999) **FI**

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ORION CORPORATION** [FI/FI]; Orionintie 1, FIN-02200 Espoo (FI).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BÄCKSTRÖM, Reijo** [FI/FI]; Poutamäentie 14 F 68, FIN-00360 Helsinki (FI). **GRANVIK, Päivi** [FI/FI]; Nissnikuntie 1 C, FIN-02430 Masala (FI). **HAIKALA, Ritva** [FI/FI]; Seilimäki 18 A 4, FIN-02180 Espoo (FI). **PELTTARI, Sirpa** [FI/FI]; Kotitontuntie 6-8 A 17, FIN-02200 Espoo (FI). **SAUKKO, Eva** [FI/FI]; Apajakuja 2, FIN-02230 Espoo

**Published:**

— Without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN**

(57) Abstract: The invention relates to levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment of congestive heart failure.

WO 01/19334 A2

Customer Number 22,852  
Attorney Docket No. 06267.0085

# DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## Pharmaceutical solutions of levosimendan

the specification of which

☒ was filed on September 8, 2000 as PCT International Application No. PCT/FI00/00761.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
FI	19991925	10 Sep. 1999	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Number	Date of Filing



Attorney Docket No. 06267.0085

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)

I hereby appoint the following attorney and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., CUSTOMER NUMBER 22,852**, Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilly, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewris, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; Roger D. Taylor, Reg. No. 28,992; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,616; Bryan C. Diner, Reg. No. 32,409; M. Paul Barker, Reg. No. 32,013; Andrew Chanho Sonu, Reg. No. 33,457; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; James W. Edmondson, Reg. No. 33,871; Michael R. McGurk, Reg. No. 32,045; Joann M. Neth, Reg. No. 36,363; Gerson S. Panitch, Reg. No. 33,751; Cheri M. Taylor, Reg. No.

FINNEGAN, HENDERSON, FARABOW, GARRETT &amp; DUNNER, L.L.P.

Attorney Docket No. 06267.0085

33,216; Charles E. Van Horn, Reg. No. 40,266; Linda A. Wadler, Reg. No. 33,218; Jeffrey A. Berkowitz, Reg. No. 36,743; Michael R. Kelly, Reg. No. 33,921; James B. Monroe, Reg. No. 33,971; Doris Johnson Hines, Reg. No. 34,629; Allen R. Jensen, Reg. No. 28,224; Lori Ann Johnson, Reg. No. 34,498; David A. Manspeizer, Reg. No. 37,540; and Steven J. Scott, Reg. No. 43,911. Please address all correspondence to **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.** 1300 I Street, N.W., Washington, D.C. 20005, Telephone No. (202) 408-4000.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

<b>Full Name of First Inventor</b>	<b>Inventor's Signature</b>	<b>Date</b>
Reijo BÄCKSTRÖM	<i>Reijo Bäckström</i>	March 25, 2002
Residence		Citizenship
Helsinki, Finland	FIX	Finnish
Post Office Address		
Poutamäentie 14 F 68, FIN-00360 Helsinki, Finland		

<b>Full Name of Second Inventor</b>	<b>Inventor's Signature</b>	<b>Date</b>
Päivi GRANVIK	<i>Päivi Granvik</i>	March 26, 2002
Residence		Citizenship
Espoo, Finland	FIX	Finnish
Post Office Address		
Kartanonkuja 6 H, FIN-02360 Espoo, Finland		

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Attorney Docket No. 06267.0085

3-00

<b>Full Name of Third Inventor</b>	<b>Inventor's Signature</b>	<b>Date</b>
Ritva HAIKALA	<i>Ritva Haikala</i>	March 27, 2002
<b>Residence</b>		<b>Citizenship</b>
Espoo, Finland	FIX	Finnish
<b>Post Office Address</b>		
Seilimäki 18 A 4, FIN-02180 Espoo, Finland		

4-00

<b>Full Name of Fourth Inventor</b>	<b>Inventor's Signature</b>	<b>Date</b>
Sirpa PELTTARI	<i>Sirpa Pelttari</i>	March 27, 2002
<b>Residence</b>		<b>Citizenship</b>
Espoo, Finland	FIX	Finnish
<b>Post Office Address</b>		
Kotitontuntie 6-8 A 17, FIN-02200 Espoo, Finland		

5-00

<b>Full Name of Fifth Inventor</b>	<b>Inventor's Signature</b>	<b>Date</b>
Eva SAUKKO	<i>Eva Saukko</i>	April 2, 2002
<b>Residence</b>		<b>Citizenship</b>
Espoo, Finland	FIX	Finnish
<b>Post Office Address</b>		
Apajakuja 2, FIN-02230 Espoo, Finland		

→

Full Name of Sixth Inventor	Inventor's Signature	Date
<u>Reija YRJÖLÄ</u>	<i>Reija Yrjölä</i>	<i>April 8, 2001</i>
Residence		Citizenship
<u>Ruutana, Finland</u>	<i>FIX</i>	Finnish
Post Office Address		
Fransilantie 4, FIN-36110 Ruutana, Finland		